XBIT
XBiotech Inc.
$2.28
+$0.06(+2.70%)
42
Overall
60
Value
25
Tech
--
Quality
Market Cap
$74.09M
Volume
61.27K
52W Range
$2.09 - $7.64
Target Price
$18.00
Company Overview
| Mkt Cap | $74.09M | Price | $2.28 |
| Volume | 61.27K | Change | +2.70% |
| P/E Ratio | -1.9 | Open | $2.28 |
| Revenue | -- | Prev Close | $2.22 |
| Net Income | $-38.5M | 52W Range | $2.09 - $7.64 |
| Div Yield | N/A | Target | $18.00 |
| Overall | 42 | Value | 60 |
| Quality | -- | Technical | 25 |
No chart data available
About XBiotech Inc.
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Sector: Healthcare
Industry: Biotechnology
Latest News
XBiotech’s New Trial: A Potential Game-Changer for Rheumatoid Arthritis Treatment?
TipRanks Clinical-Trials-Auto-Generated Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | XBIT | $2.28 | +2.7% | 61.27K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |